Raman spectroscopyin diagnosing hematological malignancies

Abstract

Summary. We reviewed literature data on Raman spectroscopy (RS) — modern modality for early diagnosis of hematological diseases.
We studied the possibilities and challenges of RS in confirming the diagnosis and evaluating effectiveness of treatment in different hematological malignancies. The results of the studies conducted showed optimistic prospects of implementing this method in clinical practice.
RS  may promote timely diagnosis of hemoblastosis and assessment of patients’ response to the treatment.

For citation: Osadchaya P.V., Garanin A.A., Rubanenko А.О. Raman spectroscopy in diagnosing hematological malignancies. Tromboz, gemostaz
i reologiya. 2025;(3):4–11. (In Russ.).

References

1. Auberger P., Tamburini-Bonnefoy J., Puissant A. Drug resistance in hematological malignancies. Int J Mol Sci. 2020;21(17):6091. DOI: 10.3390/ijms21176091.

2. Jones R.R., Hooper D.C., Zhang L. et al. Raman techniques: fundamentals and frontiers. Nanoscale Res Lett. 2019;14(1):231. DOI: 10.1186/s11671‑019‑3039‑2.

3. Auner G.W., Koya S.K., Huang C. et al. Applications of Raman spectroscopy in cancer diagnosis. Cancer Metastasis Rev. 2018;37(4):691–717. DOI: 10.1007/s10555‑018‑9770‑9.

4. Serebrennikova K.V., Berlina A.N., Sotnikov D.V. et al. Raman scattering-based biosensing: New prospects and opportunities. Biosens (Basel). 2021;11(12):512. DOI: 10.3390/bios11120512.

5. Liang H., ShiR., Wang H., Zhou Y. Advances in the application of Raman spectroscopy in haematological tumours. Front Bioeng Biotechnol. 2023;10:1103785. DOI:10.3389/fbioe.2022.1103785.

6. Newell L.F., Cook R.J. Advances in acute myeloid leukemia. BMJ.2021;375:n2026. DOI: 10.1136/BMJ.n2026.

7. Xiao H., Liang S., Wang L. Competing endogenous RNA regulation in hematologic malignancies. Clin Chim Acta. 2020;509:108–16. DOI: 10.1016/j.cca.2020.05.045.

8. Li W., Wang L., Luo C. et al. Characteristic of Five Subpopulation leukocytes in single-cell levels based on partial principal component analysis coupled with Raman spectroscopy. Appl Spectrosc. 2020;74(12):1463–72. DOI: 10.1177/0003702820938069.

9. Leszczenko P., Borek-Dorosz A., Nowakowska A.M. et al. Towards Raman-based screening of acute lymphoblastic leukemia-type B (B-ALL) subtypes. Cancers (Basel). 2021;13(21):5483. DOI: 10.3390/cancers13215483.

10. Chen Y., Jiang P., Lei S. et al. Optical tweezers and Raman spectroscopy for single-cell classification of drug resistance in acute lymphoblastic leukemia. J Biophotonics. 2022;15(9):e202200117. DOI: 10.1002/jbio.202200117.

11. Lasalvia M., Perna G., Manti L. et al. Raman spectroscopy monitoring of MCF10A cells irradiated by protons at clinical doses. Int J Radiat Biol. 2019;95(2):207–14. DOI: 10.1080/09553002.2019.1547849.

12. Garcia-Manero G., Chien K.S., Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2020;95(11):1399–420. DOI: 10.1002/ajh.25950.

13. Komrokji R.S. Luspatercept in myelodysplastic syndromes: who and when? Hematol Oncol Clin North Am. 2020;34(2):393–400. DOI: 10.1016/j.hoc.2019.10.004.

14. Alattar N., Daud H., Al-Majmaie R. et al. Surface-enhanced Raman scattering for rapid hematopoietic stem cell differentiation analysis. Appl Opt. 2018;57(22): E184–E189. DOI: 10.1364/AO.57.00E184.

15. Giagounidis A. Myelodysplastic syndromes. Internist (Berl). 2020;61(2):175–84. (In German). DOI: 10.1007/s00108‑019‑00718‑7.

16. Zeng J., Dong M., Zhu B. et al. A new method towards the detection of DNA mutation by Surface-Enhanced Raman Spectroscopy. Talanta. 2021;223(Pt 2):121746. DOI: 10.1016/j.talanta.2020.121746.

17. Kukolj T., Lazarević J., Borojević A. et al. A single-cell Raman spectroscopy analysis of bone marrow mesenchymal stem/stromal cells to identify inter-individual diversity. Int J Mol Sci. 2022;23(9):4915. DOI: 10.3390/ijms23094915.

18. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics. CA Cancer J Clin. 2021;71(1):7–33. DOI: 10.3322/caac.21654. 

19. Ferry J.A. Scientific advances and the evolution of diagnosis, subclassification and treatment of lymphoma. Arch Med Res. 2020;51(8):749–64. DOI: 10.1016/j.arcmed.2020.05.022.

20. Nishikori M. The immune microenvironment in malignant lymphoma. Rinsho Ketsueki. 2019;60(9):1229–35. (In Japanese). DOI:10.11406/rinketsu.60.1229.

21. Gala de Pablo J., Lindley M., HiramatsuK., Goda K. High-throughput Raman flow cytometry and beyond. Acc Chem Res. 2021;54(9):2132–43. DOI:10.1021/acs.accounts.1c00001.

22. Holmes A.B., Corinaldesi C., Shen Q. et al. Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. J Exp Med. 2020;217(10):e20200483. DOI: 10.1084/ jem.20200483.

23. Rau J.V., Marini F., Fosca M. et al. Raman spectroscopy discriminates malignant follicular lymphoma from benign follicular hyperplasia and from tumour metastasis. Talanta. 2019;194:763– 70. DOI: 10.1016/j.talanta.2018.10.086.

24. Agsalda-Garcia M., ShiehT., Souza R. et al. Raman-enhanced spectroscopy (RESpect) probe for childhood non-Hodgkin lymphoma. SciMed J. 2020;2(1):1–7. DOI: 10.28991/scimedj202002011.

25. Bai Y., Yu Z., Yi S. et al. Raman spectroscopy-based biomarker screening by studying the fingerprint characteristics of chronic lymphocytic leukemia and diffuse large B-cell lymphoma. J Pharm Biomed Anal. 2020;190:113514. DOI: 10.1016/j.jpba.2020.113514.

26. Rajkumar S.V. Multiple myeloma: Every year, a new standard? Hematol Oncol. 2019;37 Suppl 1(Suppl 1):62–5. DOI:  10.1002/ hon.2586.

27. Verkleij C.P.M., Korst C.L.B.M., van de Donk N.W.C.J. Immunotherapy in multiple myeloma: when, where, and for who? Curr Opin Oncol. 2020;32(6):664–71. DOI: 10.1097/CCO.0000000000000677.

28. Shi Y., Lammers T. Combining nanomedicine and immunotherapy. Acc Chem Res. 2019;52(6):1543–54. DOI: 10.1021/acs. accounts.9b00148.

29. Dey S., Trau M., Koo K.M. Surface-enhanced Raman spectroscopy for cancer immunotherapy applications: opportunities, challenges, and current progress in nanomaterial strategies. Nanomaterials (Basel). 2020;10(6):1145. DOI: 10.3390/nano10061145.

30. Pawlyn C., Davies F.E. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660–75. DOI: 10.1182/blood201809825331.

31. Chen X., Li X., Xie J. et al. Non-invasive discrimination of multiple myeloma using label-free serum surface-enhanced Raman scattering spectroscopy in combination with multivariate analysis. Anal Chim Acta. 2022;1191:339296. DOI: 10.1016/j.aca.2021.339296.

32. Russo M., Tirinato L., Scionti F. et al. Raman spectroscopic stratification of multiple myeloma patients based on exosome profiling. ACS Omega. 2020;5(47):30436–43. DOI: 10.1021/ acsomega.0c03813.

33. Morrish R., Yim K.H.W., Pagliara S. et al. Single-cell label-free probing of chromatin dynamics during B lymphocyte maturation. Front Cell Dev Biol. 2021;9:646616. DOI: 10.3389/fcell.2021.646616.

34. Ferreira B., Caetano J., Barahona F. et al. Liquid biopsies for multiple myeloma in a time of precision medicine. J Mol Med (Berl). 2020;98(4):513–25. DOI: 10.1007/s00109020018979.

35. Dell’Olio F., Su J., Huser T. et al. Photonic technologies for liquid biopsies: Recent advances and open research challenges. Laser Phot Rev. 2021;15(1):2000255. DOI: 10.1002/lpor.202000255.